This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Based in New Haven, CT, Alexion Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of life-transforming drugs, for the treatment of patients with ultra-rare disorders. The company’s complement franchise consists of key growth driver, Soliris, which is approved for the treatment of two severe and ultra-rare disorders resulting from chronic uncontrolled activation of the complement component of the immune system — paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Soliris is also approved for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. The FDA also approved its long-acting C5 complement inhibitor, Ultomiris, for the treatment of adult patients with PNH, to be administered every eight weeks. In October 2019, the FDA approved the use of Ultomiris as a treatment for adult and pediatric (one month of age or older) patients with aHUS to inhibit complement-mediated TMA.
Alexion (ALXN) Stock Up on 10Q Filing; 2016 View Retained
by Zacks Equity Research
Alexion (ALXN) has finally announced the filing of its Form 10-Q with the SEC for the period ended Sep 30, 2016 and retained its outlook for 2016.
Alexion (ALXN): Will the Stock Continue to Suffer in 2017?
by Zacks Equity Research
Given the delay in filing the 10-Q, departure of key executives, pipeline setbacks and the ongoing drug pricing issues, Alexion seems to be heading toward difficult times in 2017.
Biotech Stock Roundup: Inotek Plunges on Pipeline Setback, Kite Files IND for Study Initiation
by Arpita Dutt
Although this was a relatively slow week for the biotech sector, Inotek (ITEK) made it to the headlines on disappointing data on its lead pipeline drug.
The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, Incyte, Eli Lilly, Regeneron Pharmaceuticals and Ophthotech
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, Incyte, Eli Lilly, Regeneron Pharmaceuticals and Ophthotech
Forget Alexion (ALXN), Buy These 3 Biotech Stocks Instead
by Arpita Dutt
We advise investors to focus on biotech stocks which sport a strong Zacks Rank and have interesting pipelines/products and growth potential.
Alexion Soliris Fails in Phase II/III Delayed Graft Function Study
by Zacks Equity Research
Alexion (ALXN) reported poor top-line data from a phase II/III PROTECT study on Soliris for the prevention of delayed graft function after kidney transplantation.
Biotech Stock Roundup: Conatus Soars on Novartis Deal, Early FDA Nod for Clovis Drug
by Arpita Dutt
Biotech stocks like Conatus (CNAT) and Clovis reported positive developments this week with one company signing a deal and the other getting accelerated FDA approval for its cancer treatment.
Biotech Stock Roundup: Ophthotech Slumps on Fovista Results, Achaogen Skyrockets on Data
by Arpita Dutt
Several companies presented data this week with companies like Achaogen (AKAO) soaring while others like Ophthotech plunged.
Alexion Slips to 52-Week Low as CEO, CFO Quit amid Probe
by Zacks Equity Research
Alexion's (ALXN) shares plunged after the company's board of directors announced new leadership appointments.
Alexion Presents Data from Ultra-Rare Blood Disorder Study
by Zacks Equity Research
Alexion Pharmaceuticals (ALXN) presented new data from a dose-escalation study on ALXN1210 in patients with paroxysmal nocturnal hemoglobinuria at ASH.
Top Research Reports for Celgene, Ford & Dow Chemical
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Dow Chemical (DOW), Celgene (CELG), and Ford (F).
Stock Market News for June 16, 2016
by Zacks Equity Research
Benchmarks ended in the red for the fifth consecutive session on Wednesday after the Fed opted to keep interest rate unchanged and raised concerns about number of hikes this year